Clinical Trials Logo

Brain Infarction clinical trials

View clinical trials related to Brain Infarction.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06453252 Not yet recruiting - Stroke, Ischemic Clinical Trials

Predictors of Intracranial Atherosclerotic Disease in Posterior Circulation: a Cohort Study

Start date: June 15, 2024
Phase:
Study type: Observational

Early identification of intracranial atherosclerotic disease (ICAD) may impact the management of patients undergoing mechanical thrombectomy (MT). The aim of the study is to develop and validate a scoring system for pre-thrombectomy diagnosis of ICAD in posterior circulation large vessel/distal medium vessel occlusion strokes (LVOs/DMVOs).

NCT ID: NCT05817097 Not yet recruiting - Cerebral Infarction Clinical Trials

Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From HIRA Database

Start date: August 2023
Phase:
Study type: Observational

The goal of this observational study is to compare severity and mortality rates of acute cerebral infarction(requiring thrombolysis or endovascular recanalization) depending on the type of oral antidiabetic drug taken before the onset of cerebral infarction. Researchers will compare the group that used DPP-4 inhibitors as anti-diabetic drugs before cerebral infarction and the group that did not use them to see the effect of DPP-4 inhibitors in reducing severity of cerebral infarction.

NCT ID: NCT05559398 Not yet recruiting - Stroke, Acute Clinical Trials

Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study

GREEN
Start date: October 10, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Emergent reperfusion is the main goal for acute ischemic stroke therapy (AIS). Endovascular therapy (EVT) is recommended within 6 hrs of stroke onset, and up to 24 hrs following perfusion imaging criteria. Despite the major benefit associated with MT, more than 50% of the patients remain disabled at 3 months. Reperfusion rates after MT are critical to determine functional outcome. However, complete reperfusion is obtained in only 50 % of the patients, due to, at least in part, erratic emboli and/or no-reflow processes. The aim of this study is to evaluate the efficacy of glenzocimab in addition to EVT and compared to EVT plus placebo, whether or not associated with ntravenous thrombolysis (IVT), on functional outcome at day 90.

NCT ID: NCT03617159 Not yet recruiting - Clinical trials for Pediatric Cerebral Stroke

Role of Advanced Magnetic Resonance Imaging in Assessment of Pediatric Cerebral Stroke

Start date: October 2018
Phase:
Study type: Observational

Stroke can be ischemic, hemorrhagic, or both. Early recognition and treatment of pediatric stroke are critical in optimizing long-term functional outcomes, reducing morbidity and mortality, and preventing recurrent stroke. Neuroimaging plays a vital role in achieving this goal. Neuroimaging is usually the first step in diagnosis, helping discriminate between ischemic/hemorrhagic strokes and also in the identification of underlying potential causes. Multiparametric magnetic resonance imaging (MRI) plays a crucial role in assessing pediatric cerebral stroke including diffusion-weighted imaging (DWI), susceptibility weighted imaging (SWI) and magnetic resonance angiography (MRA).

NCT ID: NCT03318744 Not yet recruiting - Brain Infarction Clinical Trials

Antiplatelet Therapy for Silent Brain Infarction

ANTISBI
Start date: January 2018
Phase: N/A
Study type: Interventional

Silent brain infarction (SBI) or incidental infarct is common. Recent studies revealed individuals with SBI have an increased risk of future stroke. Even though the 2014 AHA/ASA recommendation for ischemic stroke and transient ischemic attack considered SBI as an entry point for secondary prevention, convincing evidence with regard to the preventive efficacy of antiplatelet therapy against incident stroke in SBI is scant. Investigators examine if antiplatelet therapy can effectively decrease the incidence of future stroke in SBI individuals.